{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T22:46:03Z","timestamp":1774392363735,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GGP20124"],"award-info":[{"award-number":["GGP20124"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Ankyloblepharon-Ectodermal Defects-Cleft Lip\/Palate (AEC) syndrome is a rare genetic disorder caused by mutations in the TP63 gene, which encodes a transcription factor essential for epidermal gene expression. A key feature of AEC syndrome is chronic skin erosion, for which no effective treatment currently exists. Our previous studies demonstrated that mutations associated with AEC syndrome lead to p63 protein misfolding and aggregation, exerting a dominant-negative effect. By performing a high-throughput screening of epigenetic and FDA-approved compounds in a co-transfection model of wild-type and mutant p63, we found that two compounds, Doxorubicin and Epirubicin, alleviate protein aggregation and restore p63 transactivation function. Moreover, treatment with these compounds reduced protein aggregation and restored the expression of keratinocyte-specific p63 target genes in primary keratinocytes derived from a conditional \u0394Np63\u03b1L514F knock-in AEC mouse model, which mimics the ectodermal defects and skin erosions characteristic of AEC syndrome. A chemical analog of Doxorubicin, diMe-Doxorubicin, which exhibits lower tissue and organ toxicity, was also found to be effective in promoting the disaggregation of mutant p63 and rescuing its transcriptional activity. Our findings identify compounds that can partially resolve mutant p63 aggregation, increase its monomeric isoform, and reactivate its transcriptional function. These results suggest potential therapeutic efficacy for treating skin erosions in AEC syndrome.<\/jats:p>","DOI":"10.1038\/s41420-025-02307-0","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:26:44Z","timestamp":1737822404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anthracyclines disaggregate and restore mutant p63 function: a potential therapeutic approach for AEC syndrome"],"prefix":"10.1038","volume":"11","author":[{"given":"Fabiana","family":"Boncimino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"D\u2019Auria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Todorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina Y.","family":"van der Zanden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-2211","authenticated-orcid":false,"given":"Jacques","family":"Neefjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-0972","authenticated-orcid":false,"given":"Anna","family":"Mandinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-5123","authenticated-orcid":false,"given":"Caterina","family":"Missero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2576-0156","authenticated-orcid":false,"given":"Stefano","family":"Sol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"2307_CR1","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1007\/s00018-008-8119-x","volume":"65","author":"E Candi","year":"2008","unstructured":"Candi E, Cipollone R, Rivetti di Val Cervo P, Gonfloni S, Melino G, Knight R. p63 in epithelial development. Cell Mol Life Sci. 2008;65:3126\u201333.","journal-title":"Cell Mol Life Sci."},{"key":"2307_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/19531","volume":"398","author":"AA Mills","year":"1999","unstructured":"Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708\u201313.","journal-title":"Nature."},{"key":"2307_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/19539","volume":"398","author":"A Yang","year":"1999","unstructured":"Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714\u20138.","journal-title":"Nature."},{"key":"2307_CR4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1101\/gad.1406006","volume":"20","author":"BC Nguyen","year":"2006","unstructured":"Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 2006;20:1028\u201342.","journal-title":"Genes Dev."},{"key":"2307_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cell.2007.02.045","volume":"129","author":"M Senoo","year":"2007","unstructured":"Senoo M, Pinto F, Crum CP, McKeon F. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell. 2007;129:523\u201336.","journal-title":"Cell."},{"key":"2307_CR6","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1101\/gad.1463206","volume":"20","author":"AB Truong","year":"2006","unstructured":"Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev. 2006;20:3185\u201397.","journal-title":"Genes Dev."},{"key":"2307_CR7","doi-asserted-by":"publisher","first-page":"18709","DOI":"10.1074\/jbc.274.26.18709","volume":"274","author":"TS Davison","year":"1999","unstructured":"Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem. 1999;274:18709\u201314.","journal-title":"J Biol Chem."},{"key":"2307_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/hmg\/10.3.221","volume":"10","author":"JA McGrath","year":"2001","unstructured":"McGrath JA, Duijf PH, Doetsch V, Irvine AD, de Waal R, Vanmolkot KR, et al. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet. 2001;10:221\u20139.","journal-title":"Hum Mol Genet."},{"key":"2307_CR9","doi-asserted-by":"crossref","unstructured":"Di Girolamo D, Di Iorio E, Missero C. Molecular and cellular function of p63 in skin development and genetic diseases. J Invest Dermatol. 2024:26;S0022-202X(24)02076-1.","DOI":"10.1016\/j.jid.2024.08.011"},{"key":"2307_CR10","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/ajmg.a.32826","volume":"149A","author":"MK Dishop","year":"2009","unstructured":"Dishop MK, Bree AF, Hicks MJ. Pathologic changes of skin and hair in ankyloblepharon-ectodermal defects-cleft lip\/palate (AEC) syndrome. Am J Med Genet A. 2009;149A:1935\u201341.","journal-title":"Am J Med Genet A."},{"key":"2307_CR11","doi-asserted-by":"publisher","first-page":"E906","DOI":"10.1073\/pnas.1713773115","volume":"115","author":"C Russo","year":"2018","unstructured":"Russo C, Osterburg C, Sirico A, Antonini D, Ambrosio R, Wurz JM, et al. Protein aggregation of the p63 transcription factor underlies severe skin fragility in AEC syndrome. Proc Natl Acad Sci USA. 2018;115:E906\u2013E915.","journal-title":"Proc Natl Acad Sci USA."},{"key":"2307_CR12","doi-asserted-by":"crossref","unstructured":"Marinello J, Delcuratolo M, Capranico G. Anthracyclines as topoisomerase II poisons: from early studies to new perspectives. Int J Mol Sci. 2018;19:3480.","DOI":"10.3390\/ijms19113480"},{"key":"2307_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJM198107163050305","volume":"305","author":"RC Young","year":"1981","unstructured":"Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med. 1981;305:139\u201353.","journal-title":"N Engl J Med."},{"key":"2307_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.semcdb.2019.05.006","volume":"98","author":"T Capeloa","year":"2020","unstructured":"Capeloa T, Benyahia Z, Zampieri LX, Blackman M, Sonveaux P. Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. Semin Cell Dev Biol. 2020;98:181\u201391.","journal-title":"Semin Cell Dev Biol."},{"key":"2307_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu K, GA V, BT P, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy - an update. Eur J Pharmacol. 2018;818:241\u201353.","journal-title":"Eur J Pharmacol."},{"key":"2307_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2921","volume":"4","author":"B Pang","year":"2013","unstructured":"Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908.","journal-title":"Nat Commun."},{"key":"2307_CR17","doi-asserted-by":"publisher","first-page":"15182","DOI":"10.1073\/pnas.1922072117","volume":"117","author":"X Qiao","year":"2020","unstructured":"Qiao X, van der Zanden SY, Wander DPA, Borras DM, Song JY, Li X, et al. Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proc Natl Acad Sci USA. 2020;117:15182\u201392.","journal-title":"Proc Natl Acad Sci USA."},{"key":"2307_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/978-981-15-0602-4_25","volume":"1206","author":"Y Wang","year":"2019","unstructured":"Wang Y, Le WD. Autophagy and ubiquitin-proteasome system. Adv Exp Med Biol. 2019;1206:527\u201350.","journal-title":"Adv Exp Med Biol."},{"key":"2307_CR19","doi-asserted-by":"publisher","first-page":"H2541","DOI":"10.1152\/ajpheart.01052.2008","volume":"295","author":"J Liu","year":"2008","unstructured":"Liu J, Zheng H, Tang M, Ryu YC, Wang X. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am J Physiol Heart Circ Physiol. 2008;295:H2541\u2013H2550.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"2307_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11906-009-0068-8","volume":"11","author":"MJ Ranek","year":"2009","unstructured":"Ranek MJ, Wang X. Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy. Curr Hypertens Rep. 2009;11:389\u201395.","journal-title":"Curr Hypertens Rep."},{"key":"2307_CR21","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","volume":"112","author":"M Lotrionte","year":"2013","unstructured":"Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D\u2019Ascenzo F, Malavasi V, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112:1980\u20134.","journal-title":"Am J Cardiol."},{"key":"2307_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7326\/0003-4819-125-1-199607010-00008","volume":"125","author":"LincoffAM Shan K,","year":"1996","unstructured":"Shan K, Lincoff AM, Young JB.Anthracycline-induced cardiotoxicity. Ann Intern Med.1996;125:47\u201358.","journal-title":"Ann Intern Med."},{"key":"2307_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1684\/ejd.2010.0931","volume":"20","author":"H Tomkova","year":"2010","unstructured":"Tomkova H, Fujimoto W, Uchida T, Macko J, Gaillyova R, Buckova H. AEC syndrome caused by heterozygous mutation in the SAM domain of p63 gene. Eur J Dermatol. 2010;20:411\u20133.","journal-title":"Eur J Dermatol."},{"key":"2307_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ajmg.1320530207","volume":"53","author":"M Pinheiro","year":"1994","unstructured":"Pinheiro M, Freire-Maia N. Ectodermal dysplasias: a clinical classification and a causal review. Am J Med Genet. 1994;53:153\u201362.","journal-title":"Am J Med Genet."},{"key":"2307_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0006-291X(03)01216-6","volume":"307","author":"KI Kim","year":"2003","unstructured":"Kim KI, Zhang DE. ISG15, not just another ubiquitin-like protein. Biochem Biophys Res Commun. 2003;307:431\u20134.","journal-title":"Biochem Biophys Res Commun."},{"key":"2307_CR26","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1172\/JCI61762","volume":"122","author":"YJ Jeon","year":"2012","unstructured":"Jeon YJ, Jo MG, Yoo HM, Hong SH, Park JM, Ka SH, et al. Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. J Clin Invest. 2012;122:2622\u201336.","journal-title":"J Clin Invest."},{"key":"2307_CR27","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1074\/jbc.M208123200","volume":"278","author":"M Liu","year":"2003","unstructured":"Liu M, Li XL, Hassel BA. Proteasomes modulate conjugation to the ubiquitin-like protein, ISG15. J Biol Chem. 2003;278:1594\u2013602.","journal-title":"J Biol Chem."},{"key":"2307_CR28","doi-asserted-by":"publisher","first-page":"e16422","DOI":"10.1371\/journal.pone.0016422","volume":"6","author":"LM Wood","year":"2011","unstructured":"Wood LM, Sankar S, Reed RE, Haas AL, Liu LF, McKinnon P, et al. A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway. PLoS ONE. 2011;6:e16422.","journal-title":"PLoS ONE."},{"key":"2307_CR29","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/0008-5472.CAN-05-1123","volume":"66","author":"SD Desai","year":"2006","unstructured":"Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin\/26S proteasome pathway. Cancer Res. 2006;66:921\u20138.","journal-title":"Cancer Res."},{"key":"2307_CR30","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.4049\/jimmunol.157.9.4100","volume":"157","author":"J D\u2019Cunha","year":"1996","unstructured":"D\u2019Cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight E Jr, Borden EC. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol. 1996;157:4100\u20138.","journal-title":"J Immunol."},{"key":"2307_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12513","volume":"7","author":"JH Park","year":"2016","unstructured":"Park JH, Yang SW, Park JM, Ka SH, Kim JH, Kong YY, et al. Positive feedback regulation of p53 transactivity by DNA damage-induced ISG15 modification. Nat Commun. 2016;7:12513.","journal-title":"Nat Commun."},{"key":"2307_CR32","first-page":"670","volume":"19","author":"RB Weiss","year":"1992","unstructured":"Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19:670\u201386.","journal-title":"Semin Oncol."},{"key":"2307_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00003495-199447020-00002","volume":"47","author":"DJ Booser","year":"1994","unstructured":"Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs. 1994;47:223\u201358.","journal-title":"Drugs."},{"key":"2307_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/7651_2018_131","volume":"1879","author":"S Sol","year":"2019","unstructured":"Sol S, Antonini D, Missero C. Isolation and enrichment of newborn and adult skin stem cells of the interfollicular epidermis. Methods Mol Biol. 2019;1879:119\u201332.","journal-title":"Methods Mol Biol."},{"key":"2307_CR35","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/sj.cdd.4401926","volume":"13","author":"E Candi","year":"2006","unstructured":"Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A, et al. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ. 2006;13:1037\u201347.","journal-title":"Cell Death Differ."},{"key":"2307_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/emmm.201100199","volume":"4","author":"G Ferone","year":"2012","unstructured":"Ferone G, Thomason HA, Antonini D, De Rosa L, Hu B, Gemei M, et al. Mutant p63 causes defective expansion of ectodermal progenitor cells and impaired FGF signalling in AEC syndrome. EMBO Mol Med. 2012;4:192\u2013205.","journal-title":"EMBO Mol Med."},{"key":"2307_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1097-2765(00)80002-7","volume":"1","author":"H Hermeking","year":"1997","unstructured":"Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, et al. 14-3-3sigma is a p53-regulated inhibitor of G2\/M progression. Mol Cell. 1997;1:3\u201311.","journal-title":"Mol Cell."}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02307-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:26:49Z","timestamp":1737822409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02307-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2307"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02307-0","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests, which may be considered potential competing interests: AM is a co-founder (with equity) of New Frontier Bio, a consumer health company developing skincare and anti-aging products, and has equity in DermBiont, a private company advancing targeted topical therapeutics for dermatologic indications. AM, KT, FB and SS receive research support from Shiseido Inc. KT has a financial interest in New Frontier Bio. JN is a shareholder in NIHM, which aims to produce aclarubicin for clinical use. LD, SYvdZ and CM declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Approval has been obtained from the animal ethic committee at CEINGE and has been approved by the Italian Ministry of Health under the animal license 311\/2016-PR. This study does not involve human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"24"}}